financetom
Business
financetom
/
Business
/
Chinese megacity Hangzhou, home to Alibaba, lifts all home purchase curbs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chinese megacity Hangzhou, home to Alibaba, lifts all home purchase curbs
May 8, 2024 7:36 PM

BEIJING, May 9 (Reuters) - China's eastern metropolis of

Hangzhou, among the country's most thriving cities, on Thursday

said it will lift all home purchase restrictions to shore up its

real estate market, raising the prospect of other cities

following suit.

As of May 9, Hangzhou's government will no longer vet the

eligibility of potential buyers, the city housing authority said

in a notice.

Hangzhou is capital of the wealthy Zhejiang province and

boasts some of China's most desirable and expensive real estate.

That led local authorities to impose home purchase curbs to

deter speculation.

Home demand has sagged across the country since 2021 as

buyer sentiment weakened significantly, chilled by a debt crisis

among property developers and a continued decline in prices.

Hangzhou is the first city to completely abolish purchase

restrictions after a meeting of top Communist Party leaders in

April called for measures to support the property sector, said

analyst Yan Yuejin at E-house China Research and Development

Institute.

The city's decision will be "very inspiring" for other

cities that still have curbs on home purchases, Yan said.

The city of 12.5 million people is China's answer to Silicon

Valley, being home to technology majors including Alibaba Group ( BABA )

and NetEase ( NTES ). It has been a magnet for tech

talent from all over China, further elevating housing demand.

The policy change is to meet that demand and promote the

healthy development of the real estate market, the housing

authority said.

Late last month, the southwestern city of Chengdu, home to

21.4 million residents, also eased home-buying limits.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natixis and Generali in early talks for asset management tie-up, FT reports
Natixis and Generali in early talks for asset management tie-up, FT reports
Nov 25, 2024
Nov 25 (Reuters) - France's Natixis Investment Managers is holding early-stage talks with Italian insurer Generali about a potential tie-up, the Financial Times reported on Monday. The firms have not yet agreed to terms of a deal, and it remains uncertain whether the talks will lead to an agreement, the report added, citing sources. A spokesperson for BPCE, the parent...
KULR Gets US Navy Contract to Develop Technology for Battery Safety
KULR Gets US Navy Contract to Develop Technology for Battery Safety
Nov 25, 2024
09:28 AM EST, 11/25/2024 (MT Newswires) -- KULR Technology ( KULR ) said Monday it has been awarded a contract by the US Navy to develop high-temperature internal short circuit cells for improved battery safety in critical applications. The project will support a wide range of uses, particularly in the aviation sector, by allowing the simulation of extreme conditions to...
MicroStrategy Provides Update on Bitcoin Holdings
MicroStrategy Provides Update on Bitcoin Holdings
Nov 25, 2024
09:21 AM EST, 11/25/2024 (MT Newswires) -- MicroStrategy ( MSTR ) said Monday that it purchased 55,500 bitcoins for $5.4 billion in cash, at an average price of $97,862 per bitcoin between Nov. 18 and Nov. 24. As of Nov. 24, MicroStrategy ( MSTR ) owned 386,700 bitcoins, with a total purchase price of $21.9 billion and an average price...
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Nov 25, 2024
Cassava Sciences Inc. stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease. The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints. In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam...
Copyright 2023-2025 - www.financetom.com All Rights Reserved